⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BMRN News
BioMarin Pharmaceuticals Inc
Global Gene Therapy Market to Surge to USD 36.55 Billion by 2032 | MarketsandMarkets™
globenewswire.com
BIIB
ALNY
SRPT
JAZZ
PFE
JNJ
BMRN
QURE
AMGN
BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England
prnewswire.com
BMRN
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
prnewswire.com
BMRN
BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
prnewswire.com
BMRN
BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting
prnewswire.com
BMRN
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
prnewswire.com
BMRN
BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET
prnewswire.com
BMRN
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease
prnewswire.com
BMRN